Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.

ABSTRACT:

Background

Gastric cancer continues to be one of the deadliest cancers in the world and therefore identification of new drugs targeting this type of cancer is thus of significant importance. The purpose of this study was to identify and validate a therapeutic agent which might improve the outcomes for gastric cancer patients in the future.

Methodology/principal findings

Using microarray technology, we generated a gene expression profile of human gastric cancer-specific genes from human gastric cancer tissue samples. We used this profile in the Broad Institute's Connectivity Map analysis to identify candidate therapeutic compounds for gastric cancer. We found the histone deacetylase inhibitor vorinostat as the lead compound and thus a potential therapeutic drug for gastric ca

SUBMITTER: Claerhout S 

PROVIDER: S-EPMC3170379 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature